Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA By Andrew Clark, 4th December 2019
Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium By Andrew Clark, 12th November 2019
Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference By Andrew Clark, 3rd September 2019
Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019 By Andrew Clark, 26th August 2019
Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer By Andrew Clark, 8th August 2019
Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer By orrbittadmin9763, 27th December 2018
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer By orrbittadmin9763, 3rd December 2018
